The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations

[1]  A. Viale,et al.  Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers , 2022, Nature Communications.

[2]  D. Parsons,et al.  Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Dick,et al.  Reconstructing Complex Cancer Evolutionary Histories from Multiple Bulk DNA Samples Using Pairtree , 2022, Blood cancer discovery.

[4]  J. Trent,et al.  Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion , 2021, Cancer Research.

[5]  B. Knoppers,et al.  Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation. , 2021, JCO precision oncology.

[6]  David C. Jones,et al.  The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets , 2021, Cancer discovery.

[7]  Aman N. Patel,et al.  Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing , 2021, Cancer discovery.

[8]  U. Tabori,et al.  Pilot study of nivolumab in pediatric patients with hypermutant cancers. , 2021 .

[9]  A. Borkhardt,et al.  Comprehensive germline-genomic and clinical profiling in 160 unselected children and adolescents with cancer , 2021, European Journal of Human Genetics.

[10]  N. Schultz,et al.  Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors , 2021, Nature Cancer.

[11]  Michael M. Khayat,et al.  Germline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children's Oncology Group. , 2020, Journal of the National Cancer Institute.

[12]  N. Tommerup,et al.  Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes , 2020, PLoS genetics.

[13]  Andrew Roth,et al.  PyClone-VI: scalable inference of clonal population structures using whole genome data , 2020, BMC Bioinformatics.

[14]  Heather L. Mulder,et al.  Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations , 2020, Nature Communications.

[15]  David M. Thomas,et al.  Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer , 2020, Nature medicine.

[16]  F. Cheng,et al.  Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors , 2020, Nature Communications.

[17]  David M. Thomas,et al.  Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. , 2020, JAMA oncology.

[18]  S. Morganella,et al.  A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies , 2020, Nature Cancer.

[19]  Michael C. Rusch,et al.  Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. , 2020, Blood cancer discovery.

[20]  Aman N. Patel,et al.  Estimated number of adult survivors of childhood cancer in United States with cancer‐predisposing germline variants , 2019, Pediatric blood & cancer.

[21]  D. Haussler,et al.  Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design , 2019, Cell reports.

[22]  B. Al-Lazikani,et al.  A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations , 2019, European journal of cancer.

[23]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[24]  Nada Jabado,et al.  Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs , 2018, Nature.

[25]  P. Agius,et al.  Immunogenic neoantigens derived from gene fusions stimulate T cell responses , 2019, Nature Medicine.

[26]  David M. Thomas,et al.  Therapeutic implications of germline genetic findings in cancer , 2019, Nature Reviews Clinical Oncology.

[27]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[28]  K. Offit,et al.  Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes , 2018, Human mutation.

[29]  Xiaotu Ma,et al.  Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome , 2018, Nature Communications.

[30]  Nicola D. Roberts,et al.  Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors , 2018, Science.

[31]  Sarah A. Teichmann,et al.  Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors , 2018, Science.

[32]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[33]  Roland Eils,et al.  Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort , 2018 .

[34]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[35]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[36]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[37]  Xin Zhou,et al.  Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors , 2018, Nature.

[38]  W. Chung,et al.  Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience , 2017, Front. Pediatr..

[39]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[40]  P. Varlet,et al.  Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial , 2017, Clinical Cancer Research.

[41]  P. Lønning,et al.  Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.

[42]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[43]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[44]  Peter J. Park,et al.  NGSCheckMate: software for validating sample identity in next-generation sequencing studies within and across data types , 2017, Nucleic acids research.

[45]  Krishnendu Chatterjee,et al.  Reconstructing metastatic seeding patterns of human cancers , 2017, Nature Communications.

[46]  Arie Perry,et al.  Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy , 2016, Neuro-oncology.

[47]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[49]  J. Schiffman,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. , 2016, The Lancet. Oncology.

[50]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[51]  B. Crompton,et al.  Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.

[52]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[53]  J. Khan,et al.  MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research , 2016, Clinical Cancer Research.

[54]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[55]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[56]  Florian Engert,et al.  Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.

[57]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[58]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[59]  Gudrun Schleiermacher,et al.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.

[60]  Sven Rahmann,et al.  Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.

[61]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[62]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[63]  F. Speleman,et al.  Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[65]  R. Norris,et al.  Challenges and opportunities in childhood cancer drug development , 2012, Nature Reviews Cancer.

[66]  Alberto Policriti,et al.  GapFiller: a de novo assembly approach to fill the gap within paired reads , 2012, BMC Bioinformatics.

[67]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[68]  Å. Borg,et al.  Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes , 2008, Familial Cancer.

[69]  A. Howell,et al.  A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients , 2002, British Journal of Cancer.

[70]  J. Birch,et al.  Malignant disease in the mothers of a population-based series of young adults with bone and soft tissue sarcomas. , 1991, British Journal of Cancer.

[71]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[72]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.